the vaccine – Page 106 – Communicable Diseases Research

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

COVID-19 바이러스학, 백신, 변이체 및 치료제에 대한 종합적인 검토

Review

Published on 2021-07-092022-09-11
Journal: Current medical science [Category] SARS, 변종, 신약개발, 유전자 메커니즘, 치료기술, 치료제,

Willingness to Receive the COVID-19 and Seasonal Influenza Vaccines among the Saudi Population and Vaccine Uptake during the Initial Stage of the National Vaccination Campaign: A Cross-Sectional Survey

Article

Published on 2021-07-082022-10-28
Journal: Vaccines [Category] COVID-19,

Exploring Psychological Factors for COVID-19 Vaccination Intention in Taiwan

Article

Published on 2021-07-082022-10-28
Journal: Vaccines [Category] COVID-19,

The SARS-CoV-2 Vaccine Hesitancy Among the General Population: A Large Cross-Sectional Study From Kuwait

Preventive Medicine

Published on 2021-07-082022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] approved complex conducted COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 virus cross-sectional dismissal effective effort examined Factor Hesitancy identify information Kuwait majority Misconception overcome pandemic positive Prevalence questionnaire responders Safe SARS-CoV-2 second wave the vaccine Vaccine Vaccine hesitancy Vaccine uptake
[DOI] 10.7759/cureus.16261 PMC 바로가기 [Article Type] Preventive Medicine

Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Research

Published on 2021-07-082022-10-28
Journal: Tropical Diseases, Travel Medicine and Vaccines [Category] COVID-19,

[키워드] acute respiratory syndrome amino acid sequence amino acids antigenic antigenicity approach candidate vaccine carried catastrophic cell-mediated immune chimeric clone coronavirus Coronavirus-2 COVID-19 CTL epitope docking E protein effective epitope Epitopes expression Final Health HTL epitope humoral IEDB immunoinformatics lack M protein molecular Multi-epitope Multi-epitope vaccine N protein ORF1a physicochemical property Plasmid polyprotein predict Protective Protein Proteins ProtParam tool Result S protein SARS-CoV-2 structural protein the vaccine TLR3 Treatment Vaccine Viral protein were used while
[DOI] 10.1186/s40794-021-00147-1 PMC 바로가기 [Article Type] Research

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Research

Published on 2021-07-082022-10-30
Journal: JAMA Oncology [Category] COVID-19,

[키워드] 95% CI Administered administration adverse effect adverse event Adverse reaction age antibody production anticancer appear blood cell counts BNT162b2 BNT162b2 vaccine Campus Cancer Chemotherapy Cohort cohort study collected conducted Control controls COVID-19 case COVID-19 infection determine division Effect Efficacy Efficacy and safety electronic medical record enrolled evaluate evaluated exposure finding first dose Future Health care worker healthy healthy individuals high-risk population IgG Importance incidence initiated leukopenia liver enzyme measure men objective occur occurred Odds ratio of BNT162b2 participant Patient patients Patients with cancer Phase 3 Point populations rate ratio reached real-world data receiving reduced Regulatory Relevance reported Result Safe SARS-CoV-2 BNT162b2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose Seroconversion serologic seronegative patients Seronegativity seropositive serum serum sample setting Sociodemographic characteristics status Testing the healthy the patient the SARS-CoV-2 the vaccine therapy toxic Treatment Trial trials vaccination Vaccine vaccine dose was used
[DOI] 10.1001/jamaoncol.2021.2675 PMC 바로가기 [Article Type] Research

COVID-19: Myths and Reality

Covid-19 : 신화와 현실

Review

Published on 2021-07-082022-09-10
Journal: Biochemistry. Biokhimiia [Category] SARS, 유전자 메커니즘, 치료법,

[키워드] ACE2 Activation angiotensin antagonists Antigen Antiviral approved binding affinity caused Cell cell membrane cell types cellular receptors Characteristics COVID‐19 COVID‑19 vaccine COVID‑19 cytoplasm facilitation feature Features furin-like protease fusion global public health hemagglutinin highly pathogenic human Angiotensin-converting enzyme hypothetical immune system immune system evasion immunological infectious agent Influenza Influenza virus Interaction mechanism molecular myth open other coronavirus other coronaviruses outbreak pandemic Pathogenesis pathogenic physiological pre-fusion Protein RBD reagents REALITY receptor Receptor binding Receptor-binding domain receptors Respiratory disease S protein SARS‑CoV‑2 similarity Strains Structure surface antigen the cell the RBD the receptor-binding domain the S protein the vaccine the viral nucleocapsid transition Treatment Trigger triggers vaccine production Vaccines Viral viral envelope virion virions virus viruses
[DOI] 10.1134/S0006297921070026 PMC 바로가기 [Article Type] Review

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Research

Published on 2021-07-082022-10-05
Journal: Nature [Category] 변종,

[키워드] Alpha variant anti-RBD antibody Antibody neutralization AstraZeneca B.1.1.7 B.1.617 B.1.617.2 binding collected convalescent individual convalescent individuals COVID-19 COVID-19 vaccine Delta delta variant dominant dose epitope examined faster France immune evasion include India individual individual with COVID-19 individuals inhibitory effect less Lineage monoclonal antibodies monoclonal antibody Mutation N-terminal domain neutralization Neutralizing NTD onset of symptom other variants Pfizer RBD Region returned SARS-CoV-2 SARS-CoV-2 variant sensitivity sera Spike protein Spread spread to strain subtype the receptor-binding domain the SARS-CoV-2 the spike protein the vaccine titre Vaccine variants
[DOI] 10.1038/s41586-021-03777-9 [Article Type] Research

Policy-Relevant Attitudes Toward COVID-19 Vaccination: Associations With Demography, Health Risk, and Social and Political Factors

Public Health

Published on 2021-07-062022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, SARS,

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Clinical Trial

Published on 2021-07-062022-10-05
Journal: JAMA [Category] 임상,

[키워드] 95% CI adverse event Adverse reaction age aluminum Analysis Bahrain Chinese clinical contributed COVID-19 COVID-19 vaccines Data collection data set dose doses double-blind Effect effective vaccine Efficacy efficacy analysis Enrollment evaluate Evidence Final Follow-up group groups had no hydroxide inactivated Inactivated vaccine injection interim analysis Intramuscular injection laboratory-confirmed median men occurred Older outcome participant per 1000 person-years phase 3 trial Primary outcome randomization Randomized randomized clinical trial reaction receive reduced resulting risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose secondary outcome Serious Adverse Event Severe case severe COVID-19 significantly strain symptomatic the vaccine Treatment United Arab Emirate Vaccine vaccine dose was collected
[DOI] 10.1001/jama.2021.8565 PMC 바로가기 [Article Type] Clinical Trial